Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Some BCBS insurance plans have reduced or eliminated weight loss drug coverage due to rising costs, although it may still be covered for other indications, such as cardiovascular risk reduction and liver disease (MASH)
These preclinical insights have been validated in large-scale clinical trials.The FLOW trial (n = 3,533) showed that once-weekly subcutaneous administration of semaglutide (1.0 mg) significantly reduced the risk of a renal composite endpointincluding 50% decline in eGFR, renal failure, or cardiovascular deathby 24% in patients with T2DM and chronic kidney disease (CKD) (HR = 0.76, 95% CI: 0.660.88
doi:10.1007/s00520-021-06060-9
it also appears that it may affect lipolysis by binding to the MC5R
